{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T20:59:02Z","timestamp":1788901142925,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T00:00:00Z","timestamp":1446854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie (US)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40257-015-0161-5","type":"journal-article","created":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T02:13:31Z","timestamp":1446862411000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials"],"prefix":"10.1007","volume":"17","author":[{"given":"Kim A.","family":"Papp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahinda","family":"Karunaratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendell","family":"Valdecantos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,7]]},"reference":[{"issue":"5","key":"161_CR1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a01. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","journal-title":"J Am Acad Dermatol."},{"key":"161_CR2","unstructured":"Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis, 2009. http:\/\/www.dermatology.ca\/psoriasisguidelines . Accessed Jan 6, 2015."},{"issue":"Suppl 2","key":"161_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","volume":"23","author":"D Pathirana","year":"2009","unstructured":"Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23(Suppl 2):1\u201370.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"985","key":"161_CR4","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/pgmj.2007.061473","volume":"83","author":"A MacDonald","year":"2007","unstructured":"MacDonald A, Burden AD. Psoriasis: advances in pathophysiology and management. Postgrad Med J. 2007;83(985):690\u20137.","journal-title":"Postgrad Med J."},{"issue":"1","key":"161_CR5","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2009.08.026","volume":"62","author":"A Menter","year":"2010","unstructured":"Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section\u00a05. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62(1):114\u201335.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"161_CR6","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2009.09.014","volume":"63","author":"RG Langley","year":"2010","unstructured":"Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010;63(3):457\u201365.","journal-title":"J Am Acad Dermatol."},{"issue":"9625","key":"161_CR7","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665\u201374.","journal-title":"Lancet."},{"issue":"9625","key":"161_CR8","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","volume":"371","author":"KA Papp","year":"2008","unstructured":"Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675\u201384.","journal-title":"Lancet."},{"issue":"4","key":"161_CR9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med."},{"issue":"9843","key":"161_CR10","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","volume":"380","author":"K Papp","year":"2012","unstructured":"Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380(9843):738\u201346.","journal-title":"Lancet."},{"issue":"1","key":"161_CR11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106\u201315.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"161_CR12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","volume":"158","author":"JH Saurat","year":"2008","unstructured":"Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558\u201366.","journal-title":"Br J Dermatol."},{"issue":"9","key":"161_CR13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1468-3083.2010.03944.x","volume":"25","author":"JP Ortonne","year":"2011","unstructured":"Ortonne JP, Chimenti S, Reich K, Gniadecki R, Sprogel P, Unnebrink K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. J Eur Acad Dermatol Venereol. 2011;25(9):1012\u201320.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"4","key":"161_CR14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jaad.2010.03.009","volume":"64","author":"BE Strober","year":"2011","unstructured":"Strober BE, Poulin Y, Kerdel FA, Langley RG, Gu Y, Gupta SR, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64(4):671\u201381.","journal-title":"J Am Acad Dermatol."},{"issue":"1","key":"161_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.dsi.2012.07.004","volume":"31","author":"T-S Wang","year":"2013","unstructured":"Wang T-S, Tsen-Fang T. Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept. Dermatologica Sinica. 2013;31(1):11\u20138.","journal-title":"Dermatologica Sinica."},{"issue":"2","key":"161_CR16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jaad.2009.08.040","volume":"63","author":"R Bissonnette","year":"2010","unstructured":"Bissonnette R, Bolduc C, Poulin Y, Guenther L, Lynde CW, Maari C. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol. 2010;63(2):228\u201334.","journal-title":"J Am Acad Dermatol."},{"issue":"2","key":"161_CR17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jaad.2006.12.003","volume":"57","author":"M Papoutsaki","year":"2007","unstructured":"Papoutsaki M, Chimenti MS, Costanzo A, Talamonti M, Zangrilli A, Giunta A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol. 2007;57(2):269\u201375.","journal-title":"J Am Acad Dermatol."},{"issue":"7","key":"161_CR18","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/j.1365-2230.2008.03161.x","volume":"34","author":"C Ryan","year":"2009","unstructured":"Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol. 2009;34(7):784\u20138.","journal-title":"Clin Exp Dermatol."},{"issue":"4","key":"161_CR19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","volume":"55","author":"KB Gordon","year":"2006","unstructured":"Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006;55(4):598\u2013606.","journal-title":"J Am Acad Dermatol."},{"issue":"3","key":"161_CR20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1365-2133.2012.11041.x","volume":"167","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167(3):658\u201367.","journal-title":"Br J Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0161-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-015-0161-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0161-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:06:35Z","timestamp":1553612795000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-015-0161-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["161"],"URL":"https:\/\/doi.org\/10.1007\/s40257-015-0161-5","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,7]]}}}